Capricor Therapeutics is trading 5% up at $9.00, apparently aligned with stronger growth-stock sentiment as the Nasdaq rises despite biotech weakness.
- No new company-specific catalyst clearly explains the gain.
- A lawsuit announcement revisited FDA concerns and earlier July stock declines but explicitly did not link the September 16 release to today’s movement.
- The advance is outperforming the broader biotech sector on September 16, 2026.